Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

Abstract:

:Sitagliptin is a once-daily, orally active, competitive and fully reversible inhibitor of dipeptidyl peptidase 4, the enzyme that is responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1. It is the first in this new class of antihyperglycaemic agents to gain regulatory approval for the treatment of Type 2 diabetes, both as a monotherapy and for use in combination with metformin or a thiazolidinedione. In clinical trials of < or = 1-year duration, sitagliptin improves glycaemic control by reducing both fasting and postprandial glucose concentrations, leading to clinically meaningful reductions in glycosylated haemoglobin levels. It is safe and well tolerated, with a side-effect profile that is similar to that of the placebo, a low incidence of hypoglycaemia and body weight neutrality. Further clinical experience with sitagliptin will reveal its long-term durability, safety and efficacy.

authors

Deacon CF

doi

10.1517/13543784.16.4.533

subject

Has Abstract

pub_date

2007-04-01 00:00:00

pages

533-45

issue

4

eissn

1354-3784

issn

1744-7658

journal_volume

16

pub_type

杂志文章,评审
  • Investigational therapies for celiac disease.

    abstract::Celiac disease is an autoimmune condition affecting genetically susceptible individuals. It is produced by the ingestion of gluten contained in wheat, rye, barley, and related products. The only treatment currently available is strict adherence to a gluten-free diet for life. This requirement for dietary compliance is...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903369333

    authors: Rodrigo L

    更新日期:2009-12-01 00:00:00

  • Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens.

    abstract:BACKGROUND:Potent new drugs against multidrug-resistant Gram-negative bacteria, namely Pseudomonas aeruginosa and Acinetobacter spp. and pan-drug-resistant Klebsiella pneumoniae, which constitute an increasing medical threat, are almost absent from the future pharmaceutical pipeline. OBJECTIVE:This drug evaluation foc...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.5.749

    authors: Poulakou G,Giamarellou H

    更新日期:2008-05-01 00:00:00

  • Pharmacology and clinical assessment of cariporide for the treatment coronary artery diseases.

    abstract::Myocardial protection through pharmacological approaches represents a large therapeutic challenge and is an important therapeutic strategy in patients with coronary artery disease, particularly after myocardial infarction. Extensive animal experiments have repeatedly demonstrated the efficacy of sodium-hydrogen exchan...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.5.1099

    authors: Karmazyn M

    更新日期:2000-05-01 00:00:00

  • New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future.

    abstract:IMPORTANCE OF THE FIELD:Antiangiogenic strategies are affording considerable interest and have become a major milestone in therapeutics of various adult cancers. However, progress has been slow to expand such therapies to patients with pediatric solid malignancies. AREAS COVERED IN THIS REVIEW:This review discusses th...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.487654

    authors: Taylor M,Rössler J,Geoerger B,Vassal G,Farace F

    更新日期:2010-07-01 00:00:00

  • Novel inhibitors of the early steps of the HIV-1 life cycle.

    abstract::Considerable advances have been made on compounds that are active as inhibitors of HIV entry and fusion. The discovery of chemokines a few years ago focused the attention on coreceptor inhibitors in addition to fusion and attachment blockers. During the last 5 years, there has been an intense research activity from bo...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.1.11

    authors: Citterio P,Rusconi S

    更新日期:2007-01-01 00:00:00

  • Gene therapy for Parkinson's disease: review and update.

    abstract::Gene transfer technology is under exploration to find therapies for the treatment of Parkinson's disease (PD) and other neurodegenerative disorders. The technology of genetic transfer can also be used as a neurobiological tool to understand the role of various genes in animal models of neurodegeneration. We describe t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.8.10.1551

    authors: Frim DM,Kang UJ

    更新日期:1999-10-01 00:00:00

  • Oral amphipathic peptides as therapeutic agents.

    abstract::Cholesterol can promote inflammation by its ability to stimulate the production of reactive oxygen species that result in the formation of pro-inflammatory oxidised phospholipids. High-density lipoproteins (HDLs) are part of the innate immune response and can be either pro- or anti-inflammatory independently of plasma...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.1.13

    authors: Reddy ST,Anantharamaiah GM,Navab M,Hama S,Hough G,Grijalva V,Garber DW,Datta G,Fogelman AM

    更新日期:2006-01-01 00:00:00

  • Drugs in preclinical to phase II clinical development for the treatment of erectile dysfunction.

    abstract:INTRODUCTION:Erectile function is an important aspect in the quality of life of many men. For men with erectile dysfunction (ED), a spectrum of treatment options exists. Novel therapies for ED are currently being developed in order to delay surgical placement of a penile prosthesis - the final step in the management of...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1324570

    authors: Smith-Harrison L,Starke NR,Smith RP,Kovac JR

    更新日期:2017-06-01 00:00:00

  • Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment options.

    abstract:BACKGROUND:Peritoneal carcinomatosis (PC) is a challenging consequence of certain malignancies, associated with a poor prognosis and limited treatment options. Generally, PC has been treated similarly to metastatic cancers of the primary tumor, but associated with worse outcomes when compared to other sites of metastat...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780902939151

    authors: Davies JM,O'Neil B

    更新日期:2009-07-01 00:00:00

  • INH-A21: a donor-selected Staphylococcal human immune globulin for the prevention of late-onset neonatal Staphylococcal infection.

    abstract::INH-A21 is an experimental human immune globulin for intravenous infusion (IGIV) derived from donors specifically selected for elevated levels of antibodies against the Staphylococcal fibrinogen-binding proteins, serine aspartate dipeptide repeat G and clumping factor A. Phase II results demonstrated that infusions of...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.15.6.703

    authors: Bloom BT

    更新日期:2006-06-01 00:00:00

  • Planned, ongoing and recently completed clinical trials for atherosclerosis prevention and regression: an update.

    abstract::Recent landmark studies using hydroxy-methyl-glutaryl-Co-enzyme A reductase inhibitors (HMG-CoA reductase inhibitors or statins), specifically, pravastatin and simvastatin, have led to dramatic changes in medical practice. These clinical trials have demonstrated that clinicians can impact coronary morbidity and mortal...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.1.31

    authors: Mellies M,McGovern M

    更新日期:1997-01-01 00:00:00

  • CDK inhibitors in clinical development for the treatment of cancer.

    abstract::Cyclin-dependent protein kinases (CDKs) are key regulators of the cell division cycle, whose various checkpoints proliferating cells must traverse. Since CDK deregulation, either through direct or indirect means, is found in most cancer cells, pharmacological CDK inhibition has become an attractive strategy towards me...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.6.955

    authors: Fischer PM,Gianella-Borradori A

    更新日期:2003-06-01 00:00:00

  • Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors.

    abstract:INTRODUCTION:Metastases to the central nervous system are the most common cause of malignant intracranial tumors in adults. Current standard of care includes surgery and radiation, but overall survival remains poor. A range of systemic therapies are emerging as promising treatment options for these patients. AREAS COV...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2020.1836154

    authors: McMahon JT,Faraj RR,Adamson DC

    更新日期:2020-12-01 00:00:00

  • Pompholyx: what's new?

    abstract:BACKGROUND:Pompholyx is a chronic relapsing inflammatory vesicobullous skin disease of the hands and feet belonging to the spectrum of eczema. Established treatments, both topical and systemic, are limited in efficacy, risk:benefit ratio and prevention of further relapses. New treatment options are needed. OBJECTIVE:T...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.6.897

    authors: Wollina U

    更新日期:2008-06-01 00:00:00

  • TACE inhibition: a new approach to treating inflammation.

    abstract::Clinical trials showing the benefits of reducing the effects of TNF- alpha in rheumatoid arthritis have highlighted the key role of the cytokine TNF- alpha in this inflammatory condition. A new approach to reducing the effects of TNF- alpha is to decrease its synthesis by inhibiting TNF- alpha converting enzyme with G...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.11.7.1003

    authors: Doggrell SA

    更新日期:2002-07-01 00:00:00

  • Cardiac fibrosis: emerging agents in preclinical and clinical development.

    abstract:INTRODUCTION:Myocardial fibrosis is a remarkably dynamic process mediated by different molecular pathways that represent potential targets of novel therapeutic interventions. Transforming Growth Factor-beta (TGF-β), connective Tissue Growth Factor (cTGF) and Galectin-3 (Gal-3) represent the most promising targets on wh...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2021.1868432

    authors: Spoladore R,Falasconi G,Fiore G,Di Maio S,Preda A,Slavich M,Margonato A,Fragasso G

    更新日期:2021-01-04 00:00:00

  • Pharmacological revascularisation in coronary and peripheral vascular disease.

    abstract::Therapeutic angiogenesis is a novel approach to the treatment of ischaemic or occlusive coronary and peripheral vascular disease. The therapeutic concept is based on the restoration of distal blood flow by the enlargement of existing vessels and tissue perfusion by the induction of new capillaries. Initial studies hav...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.10.1319

    authors: Tarzami ST,Singh JP

    更新日期:2004-10-01 00:00:00

  • Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials.

    abstract:INTRODUCTION:Current treatment for polycythemia vera (PV) is limited and primarily targets thrombosis risk. Agents targeting distinct mechanisms of action within myeloproliferation are undergoing clinical evaluation to optimize efficacy, improve tolerance and augment long term disease complications. AREA COVERED:This ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2020.1782886

    authors: Padrnos L,Mesa R

    更新日期:2020-08-01 00:00:00

  • Investigations on gossypol: past and present developments.

    abstract::Gossypol has received significant attention as a result of its potential therapeutic application as a male antifertility agent. Furthermore, recent research examining the biological activity of gossypol has revealed a number of other promising lines of enquiry. These have focused on the antitumour, antiviral and antio...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.14.11.1419

    authors: Dodou K,Anderson RJ,Small DA,Groundwater PW

    更新日期:2005-11-01 00:00:00

  • Chronic obstructive pulmonary disease: role of matrix metalloproteases and future challenges of drug therapy.

    abstract::COPD is a chronic disease of the lung that is characterised by decreased air flow and associated abnormal inflammatory responses of the lungs. A total of 80% of COPD incidences are observed in patients with history of smoking tobacco. The chronic condition of COPD is characterised by airway remodelling, which leads to...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.7.1069

    authors: Srivastava PK,Dastidar SG,Ray A

    更新日期:2007-07-01 00:00:00

  • Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.

    abstract::Major depressive disorder (MDD) affects

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903286396

    authors: Khan A

    更新日期:2009-11-01 00:00:00

  • Aripiprazole acts as a selective dopamine D2 receptor partial agonist.

    abstract::Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile. It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.6.771

    authors: Wood M,Reavill C

    更新日期:2007-06-01 00:00:00

  • Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status.

    abstract::This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.12.2903

    authors: Kelland LR

    更新日期:2000-12-01 00:00:00

  • Current and emerging investigational medical therapies for the treatment of overactive bladder.

    abstract::Overactive bladder (OAB) is a chronic distressing condition characterised by urinary urgency with or without urge incontinence, usually with frequency (voiding at least eight times daily) and nocturia. It affects millions of people worldwide independent of age, sex and race. The prevalence increases with age and is re...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.9.1017

    authors: Tiwari A,Naruganahalli KS

    更新日期:2006-09-01 00:00:00

  • Investigational therapies for the treatment of spinal muscular atrophy.

    abstract:INTRODUCTION:Currently, there is no cure available for the hereditary neurodegenerative disease proximal spinal muscular atrophy (SMA), which is the number one genetic killer in early childhood. However, growing knowledge of SMA pathophysiology has opened new avenues for potential therapeutic interventions. AREAS COVE...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2015.1038341

    authors: Kaczmarek A,Schneider S,Wirth B,Riessland M

    更新日期:2015-01-01 00:00:00

  • VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis.

    abstract:INTRODUCTION:Allergic rhinitis significantly impacts quality of life and current treatments are frequently unsatisfying. VTX-1463 is a potent, selective, Toll-like receptor (TLR) 8 agonist administered weekly via the intranasal route without concomitant administration of allergen for the treatment of allergic rhinitis....

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2011.583237

    authors: Horak F

    更新日期:2011-07-01 00:00:00

  • Urokinase receptor antagonists: novel agents for the treatment of cancer.

    abstract::The interaction between the urokinase receptor (uPAR) and its ligand urokinase (uPA) mediates phenomena such as tissue remodelling, chemotaxis, tumour invasion, dissemination, proliferation, and angiogenesis. The broad-spectrum of biological processes that the uPA/uPAR interaction plays a role in has led researchers t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.3.391

    authors: Weidle UH,König B

    更新日期:1998-03-01 00:00:00

  • New approaches to developing antidepressants by enhancing monoaminergic neurotransmission.

    abstract::Major depressive disorder (MDD) is a serious illness with far reaching societal and economic ramifications. The monoamine-deficiency hypothesis that depressive symptoms are associated with reductions in monoamine neurotransmission, particularly serotonin and noradrenaline, is supported by both neurochemical findings a...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.4.531

    authors: Bymaster FP,McNamara RK,Tran PV

    更新日期:2003-04-01 00:00:00

  • Prorenin receptor blockers: effects on cardiovascular complications of diabetes and hypertension.

    abstract::When the 'handle region' of the prorenin prosegment interacts with the (pro)renin receptor, the prorenin molecule partially changes the conformation to an enzymatically active state. On the other hand, the receptor triggers its own intracellular signalling pathways independent of the renin-angiotensin system (RAS). Th...

    journal_title:Expert opinion on investigational drugs

    pub_type: 社论,评审

    doi:10.1517/13543784.15.10.1137

    authors: Ichihara A,Kaneshiro Y,Suzuki F

    更新日期:2006-10-01 00:00:00

  • Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels.

    abstract:INTRODUCTION:Thermo transient receptor potential (thermoTRP) channels are some of the most intensely pursued therapeutic targets of the past decade. They are considered promising targets of numerous diseases including chronic pain and cancer. Modulators of these proteins, in particular TRPV1-4, TRPM8 and TRPA1, have re...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2020.1825680

    authors: Fernández-Carvajal A,González-Muñiz R,Fernández-Ballester G,Ferrer-Montiel A

    更新日期:2020-11-01 00:00:00